[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 217
1. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW: Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Oct;19(10):1759-64
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL.
  • CONCLUSIONS: The combination of gemcitabine and bortezomib is a less active and more toxic regimen in relapsed HL than other currently available treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Proteasome Endopeptidase Complex / blood. Pyrazines / administration & dosage. Pyrazines / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 Apr;92(4):568-9 [17488673.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2482-9 [17036355.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1313-9 [17613759.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2627-8 [10561333.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Blood. 2001 May 1;97(9):2798-807 [11313274.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1145-54 [12631620.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):88-95 [12816986.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2597-8 [12826633.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] J Surg Res. 2003 Jul;113(1):88-95 [12943815.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):279-90 [15026548.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53 [15197486.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1839-42 [15878978.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1654-61 [16085692.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):533-40 [16546967.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • (PMID = 18504251.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00262860
  • [Grant] United States / NCI NIH HHS / CA / CA-102216
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC2735068
  •  go-up   go-down


2. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M: Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica; 2007 Jan;92(1):35-41
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's lymphoma.
  • DESIGN AND METHODS: Ninety-one patients with refractory or relapsed Hodgkin's lymphoma were treated prospectively with a salvage regimen consisting of ifosfamide 2000 mg/m2 on days 1 to 4, gemcitabine 800 mg/m2 on days 1 and 4, vinorelbine 20 mg/m2 on day 1, and prednisolone 100 mg on days 1 to 4 (IGEV).
  • INTERPRETATION AND CONCLUSIONS: The high response rate, in particular the complete remission rate, the low toxicity profile, and the very high mobilizing potential of the IGEV regimen strongly suggest that patients with relapsed/refractory Hodgkin's lymphoma may benefit from the use of this salvage induction regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Hodgkin Disease / drug therapy. Ifosfamide / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / biosynthesis. Female. Humans. Male. Middle Aged. Recurrence. Stem Cell Transplantation. Treatment Outcome


3. Puig N, Pintilie M, Seshadri T, Al-Farsi K, Nagy T, Franke N, Tsang R, Keating A, Crump M, Kuruvilla J: Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica; 2010 Sep;95(9):1496-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.
  • BACKGROUND: The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear.
  • Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation.
  • DESIGN AND METHODS: We retrospectively analyzed data on 157 consecutive patients with Hodgkin's lymphoma referred to our institution for consideration of autologous stem-cell transplantation between 1999 and 2006.
  • Of those, 73 met the definition of having primary refractory disease, ie. progressive disease during first line chemotherapy or within 3 months of completion of the treatment.
  • Those patients achieving complete remission, partial remission and stable disease with symptomatic improvement after two or three cycles of salvage chemotherapy proceeded to stem cell mobilization and autologous transplantation.
  • RESULTS: From first relapse/progression, the 3-year overall survival was 76% (95% CI: 66%-89%) for the refractory cohort and 91% (95% CI: 84%-98%) for the relapsed cohort (P=0.034); the overall response rate to second-line chemotherapy was 51% and 83% (P<0.0001), respectively.
  • Three-year progression-free survival post-transplant was 49% in refractory patients and 67% in relapsed patients (P=0.21); overall survival was 75% and 91% (P=0.097), respectively.
  • CONCLUSIONS: Using the group with relapsed disease as a reference, we can conclude that the subset of patients with chemosensitive primary refractory Hodgkin's lymphoma do benefit from autologous stem-cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):332-9 [10637247.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):972-80 [10694546.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:81-5 [10707785.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):161-71 [11328296.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):467-75 [11786576.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):273-8 [12209348.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1762-7 [14630682.001]
  • [Cites] Br J Haematol. 2004 Mar;124(5):645-52 [14871252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18 [15093918.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(12):1225-9 [15094747.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):47-50 [3041599.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 1991 May 15;77(10):2292-8 [1709382.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):396-402 [7844600.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1293-9 [8826953.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):528-34 [9053474.001]
  • [Cites] Blood. 1997 Feb 1;89(3):801-13 [9028311.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):534-45 [10080597.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):73-8 [10211091.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):222-9 [10458237.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] Bone Marrow Transplant. 2005 Feb;35(3):291-8 [15558040.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):353-60 [16329112.001]
  • [Cites] Bone Marrow Transplant. 2007 Oct;40(7):651-8 [17660837.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5980-7 [19018090.001]
  • (PMID = 20460643.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2930950
  •  go-up   go-down


Advertisement
4. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ: Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Oct;12(10):1065-72
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
  • Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy for primary refractory (PR REF) or relapsed (REL) Hodgkin's lymphoma (HL); however, more than half of these patients eventually relapse and die of their disease.
  • In multivariate analysis, 3 factors were independently predictive of poor PFS: chemoresistant disease (relative risk [RR], 2.9; 95% CI, 1.7-5.0), B-symptoms at pretransplantation relapse (RR, 2.1; 95% CI, 1.3-3.4), and presence of residual disease at the time of transplantation (RR, 2.3; 95% CI, 1.1-4.8).
  • Patients with 0 or 1 of these 3 adverse factors (low-risk disease) had a 5-year PFS of 67% (95% CI, 55%-79%) compared with 37% (95% CI, 22%-52%) in those with 2 factors (intermediate-risk group) and 9% (95% CI, 0-20%) in those with all 3 factors (high-risk group) (P < .001).
  • Using a simple prognostic model, we can identify patients with high-risk disease who have predictably unfavorable outcome after ASCT and require novel therapeutic approaches.
  • [MeSH-major] Bone Marrow Transplantation / statistics & numerical data. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Transplantation, Autologous / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Recurrence. Risk. Salvage Therapy. Treatment Outcome. Tumor Burden. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084370.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med; 2010 Nov 4;363(19):1812-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
  • BACKGROUND: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30.
  • METHODS: In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.
  • CONCLUSIONS: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.
  • [MeSH-major] Hodgkin Disease / drug therapy. Immunoconjugates / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30. Chemokine CCL17 / blood. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Recurrence. Remission Induction. Young Adult


6. Mandac I, Kolonic SO: Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma. J Hematol Oncol; 2010;3:20
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.
  • BACKGROUND: A 24-year-old female patient was diagnosed with classic Hodgkin's lymphoma in clinical stage II, and combination chemotherapy followed by radiotherapy was initiated.
  • During the following 5 years, the disease progressed despite several standard therapeutic approaches, including autologous and allogeneic stem cell transplantation.
  • Evaluations after 15 months of lenalidomide treatment indicated limited disease progression.
  • CONCLUSION: Daily, long-term lenalidomide treatment provided clinical benefit and was well tolerated in a patient with relapsed, advanced classic Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Hodgkin Disease / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Blood. 2011 Nov 10;118(19):5119-25 [21937701.001]
  • [Cites] Br J Haematol. 2010 Feb;148(3):480-2 [19863533.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5404-9 [19805688.001]
  • (PMID = 20509896.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2893445
  •  go-up   go-down


7. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Sep 1;12(17):5190-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
  • PURPOSE: Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy.
  • EXPERIMENTAL DESIGN: We assessed response, toxicity, and biomarkers of angiogenesis to low-dose cyclophosphamide (50 mg p.o. o.d.) and high-dose celecoxib (400 mg p.o. b.i.d.) in adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in a multicenter phase II prospective study.
  • Patients had primarily relapsed diffuse large B-cell lymphoma (63%) were heavily pretreated (median of three regimens) and high risk (79% international prognostic index, >or=2) and 34% were relapsed after autologous stem cell transplant.
  • With a median follow-up of 8.4 months, the overall best response rate is 37% (2 complete clinical response/complete clinical response unconfirmed and 9 partial response), with 22% achieving stable disease.
  • CONCLUSIONS: Low-dose cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Celecoxib. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Prospective Studies. Recurrence. Risk Factors. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951238.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


8. Decaudin D, Levy R, Lokiec F, Morschhauser F, Djeridane M, Kadouche J, Pecking A: Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody. Anticancer Drugs; 2007 Jul;18(6):725-31
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
  • The aim of this study was to evaluate the safety and efficacy of radiolabelled rabbit polyclonal antiferritin antibody in relapsed or refractory Hodgkin's lymphoma.
  • Nine patients were treated, as the last patient died from progressive Hodgkin's lymphoma before therapeutic injection.
  • These results confirm those previously reported and show the therapeutic potential of rabbit polyclonal antiferritin antibody in relapsed or refractory Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Ferritins / immunology. Hodgkin Disease / radiotherapy. Immunoconjugates / therapeutic use. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Male. Neoplasm Staging. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762404.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoconjugates; 0 / Yttrium Radioisotopes; 9007-73-2 / Ferritins
  •  go-up   go-down


9. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2008 Oct 20;26(30):4952-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy.
  • Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).
  • We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
  • PATIENTS AND METHODS: Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance.
  • The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL.
  • Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment.
  • CONCLUSION: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Prospective Studies. Remission Induction


10. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • Thirty-three patients received involved-field radiotherapy prior to stem cell transplantation directed at symptomatic and/or bulky sites; eight patients received involved-field radiotherapy after stem cell transplantation directed at sites of persistent disease.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Female. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Aurer I, Radman I, Nemet D, Zupancić-Salek S, Bogdanić V, Mrsić M, Sertić D, Labar B: Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie; 2005 Nov;28(11):567-71
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
  • BACKGROUND: Patients with refractory Hodgkin's disease or relapsing after high-dose therapy and autografting have a poor prognosis.
  • PATIENTS AND METHODS: We treated 14 patients with relapsed or refractory Hodgkin's disease with gemcitabine.
  • 1 patient had stage IA disease, 2 patients had stage IIIB disease and 11 patients had stage IVB disease.
  • CONCLUSION: Gemcitabine is an effective treatment for Hodgkin's disease.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Croatia / epidemiology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival Rate. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249642.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol; 2006 May;17 Suppl 4:iv25-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
  • We have treated 75 transplant-eligible patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation.
  • Patients included DLBC (n = 33), follicular (n = 23), NK/T-cell (n = 3), mantle cell (n = 3) and Hodgkin's lymphoma (n = 13).
  • Most patients with indolent lymphoma also received rituximab.
  • These data confirm the efficacy and tolerability of outpatient fractionated ICE as both a salvage and mobilisation regimen in relapsed/refractory lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702181.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Minigo H, Vrhovac R, Kalac M, Jaksić B: [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease]. Acta Med Croatica; 2009 Jun;63(3):215-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease].
  • Patients with relapsed or refractory Hodgkin's disease (HD) are routinely treated with intensive chemotherapy followed by autologous stem cell transplantation (ASCT).
  • From February 1995 until October 2006, a total of 53 patients with active HD (28 male and 25 female, aged 18-60, median 29) received BEAM myeloablative treatment followed by ASCT.
  • Accordingly, in this group of patients with active disease at the time of transplantation, ASCT toxicity could be considered acceptable.
  • We conclude that BEAM myeloablative chemotherapy followed by ASCT is a very efficacious treatment for patients with relapsed or refractory HD.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Recurrence. Survival Rate. Transplantation Conditioning. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827348.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


14. Claviez A, Sureda A, Schmitz N: Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant; 2008 Oct;42 Suppl 2:S16-24
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
  • Despite the generally excellent prognosis of children and adolescents with Hodgkin's lymphoma (HL), approximately 15% of patients relapse.
  • Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking.
  • Although patients with late relapse (>12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT.
  • According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively.
  • Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors.
  • Broader use has been hampered for a long time mainly by high non-relapse mortality, offsetting the advantage of a graft-vs-lymphoma effect.
  • Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Leukemia Effect. Humans. Male. Randomized Controlled Trials as Topic. Recurrence. Risk Factors. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978738.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


15. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm; 2005 Apr;20(2):185-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
  • AIM: Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%.
  • MATERIALS AND METHODS: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed.
  • CONCLUSIONS: (90)Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Yttrium Radioisotopes / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / biosynthesis. Disease Progression. Female. Humans. Male. Middle Aged. Radioimmunotherapy / methods. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869453.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


16. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
  • Patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) were eligible for this phase II study of doxorubicin 25 mg/m2 intravenous (IV) on day 1 and topotecan 1.75 mg/m2/day IV on days 3 - 5, every 21 days.
  • Five patients (20%, 95% confidence interval 0.07, 0.42) responded with two (8%) complete remissions and three (12%) partial remissions; an additional four (16%) patients had stable disease.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • In conclusion, the combination of doxorubicin and topotecan is well tolerated and has modest activity in relapsed/refractory NHL, with occasional patients having a prolonged remission.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-major] Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


17. Gao Y, Huang HQ, Lin XB, Cai QQ, Pan ZH, Wang BF, Bu Q: [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma]. Ai Zheng; 2007 Aug;26(8):909-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory T-cell non-Hodgkin's lymphoma (T-NHL) is poor.
  • This study was to explore the prognostic factors and effective regimens for relapsed or refractory T-NHL.
  • METHODS: Clinical records of 45 patients with relapsed or refractory T-NHL, treated in Cancer Center of Sun Yat-sen University from Jan.
  • Multivariate analysis showed that serum lactate dehydrogenase (LDH) level (P=0.010), second-line Ann Arbor stage (P=0.009), second-line IPI score (P=0.015), autologous stem cell transplantation (P=0.026), performance status (P=0.002), and IMVP-16 regimen (P=0.026) were independent prognostic factors of relapsed or refractory T-NHL.
  • CONCLUSIONS: Second-line IPI score, autologous stem cell transplantation, and so on, may be independent prognostic factors for relapsed or refractory T-NHL.
  • The prognosis of this disease is poor and the addition of intensive treatments, such as stem cell transplantation, should be considered when alleviated after chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697558.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


18. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol; 2008 Jul;19(7):1312-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
  • BACKGROUND: The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT).
  • Demography at ASCT was 61% stage IV, median age 31 years (18-69), median prior treatment (tx) regimens 3 (2-7), median Hasenclever index 3 (0-6); 150 patients had responding disease [54 complete remission (CR), 96 partial remission (PR)], and 45 patients had untested relapse/refractory disease.
  • Of 119 patients attaining CR, 27 relapsed: 3 after attaining CR for >5 years and 1 after attaining CR for >10 years.
  • CONCLUSION: These data provide the longest follow-up reported for patients receiving ASCT for relapsed/refractory HL.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356139.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


19. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey T, Forman SJ, Lange T, Shizuru J, Langston A, Pulsipher MA, Sandmaier BM, Storb R, Maloney DG: Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol; 2008 Jan 10;26(2):211-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
  • PURPOSE: Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL).
  • Twenty patients (32%) had progressive disease after previous high-dose therapy with autologous HCT.
  • RESULTS: At 3 years, the estimated overall survival (OS) and progression-free survival (PFS) rates were 52% and 43%, respectively, for patients with indolent disease, and 18% and 21%, respectively, for patients with transformed disease.
  • Patients with indolent disease and related donors (n = 26) had 3-year estimated OS and PFS rates of 67% and 54%, respectively.
  • The incidences of grade 2 to 4 acute graft-versus-host disease (GVHD), grade 3 and 4 acute GVHD, and extensive chronic GVHD were 63%, 18%, and 47%, respectively.
  • CONCLUSION: Nonmyeloablative allogeneic HCT can produce durable disease-free survival in patients with relapsed or refractory indolent NHL, even in this relatively elderly and heavily pretreated cohort.
  • Outcomes were particularly good in patients with untransformed disease and related donors, whereas patients with transformed disease did poorly.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / K99-HL088021; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ: [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Ai Zheng; 2006 Apr;25(4):486-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy.
  • Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease-freely survival and overall survival of naive patients, but it's role in the second-line treatment for relapsed non-Hodgkin's lymphoma (NHL) is uncertain.
  • This study was to evaluate the efficacy of rituximab-containing salvage regimens on relapsed or refractory NHL, and observe the toxicities.
  • METHODS: Clinical data of 35 patients with relapsed or refractory NHL, treated in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • Of the 35 patients, 19 were man, and 16 were women, with a median age of 53.5 years (ranged from 21 to 77); for ECOG performance status, 33 (94.3%) scored 0-1; for international prognostic index (IPI), 20 (57.1%) scored 0-1, 7 (20%) scored 2, 4 (11.4%) scored 3, and 4 (11.4%) scored 4-5; 23 cases of diffuse large B-cell lymphoma (DLBL) accounted for 65.7% among all subtypes.
  • The median follow-up time was 12.5 months (ranged from 3 to 69 months); 2 patients were lost, 10 were died (9 died of lymphoma, and 1 died of severe hepatitis), the other patients remained alive.
  • CONCLUSION: Rituximab-containing salvage regimens are effective and well tolerated, even in extensively pretreated patients with relapsed or refractory B-cell NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Prednisone / therapeutic use. Remission Induction. Rituximab. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613686.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol; 2009 Nov 10;27(32):5404-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
  • Given its efficacy in a wide range of hematologic malignancies, we conducted a phase II trial (NHL-001) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Patients with relapsed/refractory indolent NHL were eligible, with no limit on the number of previous therapies.
  • Oral lenalidomide 25 mg was self-administered once daily on days 1 to 21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression.
  • Twenty-seven percent (six of 22) of patients with follicular lymphoma grade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy.
  • CONCLUSION: Oral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolent NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Constipation / chemically induced. Diarrhea / chemically induced. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neutropenia / chemically induced. Recurrence. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


22. Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol; 2008 Nov 10;26(32):5240-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
  • PURPOSE: To evaluate the risk of late morbidity and mortality, and to assess long-term health-related quality of life (QOL) among patients with relapsed/refractory Hodgkin's lymphoma (HL) after high-dose chemoradiotherapy (HDT) and autologous stem-cell rescue (ASCR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Resistance, Neoplasm. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Quality of Life. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. New York City / epidemiology. Radiotherapy, Adjuvant. Recurrence. Risk Assessment. SEER Program. Salvage Therapy. Surveys and Questionnaires. Time Factors. Transplantation, Autologous. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809615.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Husseini H, Maghfoor I: High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant; 2010 Mar;45(3):476-82
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
  • Fifty-eight adolescent patients with relapsed or primary refractory Hodgkin's lymphoma underwent high-dose chemotherapy (HDC) and autologous SCT (ASCT).
  • The disease had relapsed in 24 patients (41%) and was refractory to initial chemotherapy in 34 (59%).
  • One patient did not respond and nine (15%) had progressive disease.
  • At a median follow-up of 43 months from ASCT, 31 patients (53%) are alive in CR, 5 (9%) are alive with disease and 22 (38%) have died (21 from disease and 1 unrelated).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / drug therapy. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Prognosis. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734949.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, Gastineau DA, Gertz MA, Lacy MQ, Litzow MR, Tefferi A, Inwards DJ: Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant; 2006 Jun;37(11):1017-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
  • To evaluate autologous stem cell transplant (ASCT) in older patients with intermediate grade non-Hodgkin's lymphoma (NHL), the Mayo Clinic Rochester BMT database was reviewed for all patients 60 years of age and older who received ASCT for NHL between September 1995 and February 2003.
  • Autologous stem-cell transplant can be safely performed in patients 60 years or older with chemotherapy sensitive relapsed or first partial remission NHL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633361.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M, Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E: Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. Ann Oncol; 2010 Jun;21(6):1211-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
  • BACKGROUND: High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard in the treatment of patients with relapsed or refractory Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: We retrospectively analyzed the efficacy and toxicity of MINE (mesna, ifosfamide, mitoxantrone, and etoposide) alternated with ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in the treatment of 61 relapsed or refractory HL patients after ABVD-based chemotherapy.
  • RESULTS: Overall, 25 patients (41%) achieved a complete response (CR), 23 (38%) a partial response (PR), 4 (7%) a stable disease, and 8 (13%) progressed for an overall response rate of 79%.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889622.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; OD5Q0L447W / Mitoguazone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone
  •  go-up   go-down


26. Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Gerson SL, Koç ON, Lazarus HM: Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation. Contemp Clin Trials; 2008 Mar;29(2):157-64
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
  • We developed a modified statistical model based on histologic grade and other variables to describe the time-dependent outcome for autologous stem cell transplant (autotransplant) performed for non-Hodgkin's lymphoma (NHL) based on histologic grade and other variables.
  • One hundred and fourteen relapsed or refractory NHL patients were treated using BCNU 600 mg/m2, etoposide 2400 mg/m2, and cisplatin 200 mg/m2 IV followed by autotransplant.
  • At a median follow-up of 33 (range: 3 to 118) months, the estimated 5-year Kaplan-Meier probabilities of overall survival and disease-free survival were 61% and 51%, respectively.
  • Cox proportional hazards model analysis showed that proportionality did not hold for lymphoma grade, indicating that the relationship between the grade and disease-free survival differed over time.
  • The time-dependent effect of lymphoma grade on disease-free survival suggests the need for early (within first year) incorporation of novel therapeutic approaches in management of patients with indolent NHL undergoing autotransplant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Models, Statistical. Proportional Hazards Models. Time. Transplantation, Autologous. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707140.001).
  • [ISSN] 1551-7144
  • [Journal-full-title] Contemporary clinical trials
  • [ISO-abbreviation] Contemp Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


27. Miltényi Z, Keresztes K, Ujhelyi L, Kovács J, Illés A: [Nephrotic syndrome in Hodgkin's disease]. Orv Hetil; 2005 Jun 19;146(25):1357-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephrotic syndrome in Hodgkin's disease].
  • [Transliterated title] Nephrosis szindrómával járó Hodgkin-kór.
  • The authors are presenting a rare paraneoplastic syndrome in Hodgkin's disease.
  • Four months later, when the nephrosis syndrome relapsed, Hodgkin's disease was diagnosed (nodular sclerosing subtype).
  • Hodgkin's disease was staged as III/BS.
  • Polychemotherapy resulted complete remission of both Hodgkin's disease and nephrotic syndrome.
  • Causes of nephrotic syndrome in Hodgkin's disease can include renal vein thrombosis, amyloidosis or paraneoplastic syndrome.
  • Nephrotic syndrome in Hodgkin's disease may relate to dysfunction of T-cells or altered cytokine balance, but the exact pathogenesis is not known.
  • This case attracts attention that a rare cause of nephrotic syndrome can be Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Nephrotic Syndrome / diagnosis. Nephrotic Syndrome / etiology. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Glomerulonephritis / diagnosis. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106759.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


28. Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T: Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant; 2008 Apr;41(7):613-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
  • Several high-dose therapy regimens are used for autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed and refractory Hodgkin's lymphoma (HL) with variable disease response.
  • An intensified regimen of etoposide (VP-16) 2,400 mg/m(2), cyclophosphamide 7,200 mg/m(2) and carmustine (BCNU) 600 mg/m(2) (VCB) pre-auto-HSCT was developed to overcome disease recurrence.
  • A total of 43 relapsed and refractory HL patients underwent auto-HSCT between January 1992 and December 2004.
  • A total of 40 patients survived beyond day 100, 14 of whom subsequently relapsed/progressed.
  • At a median follow-up of 4.9 years (range 1.5-11.4 years), 26 patients (60%) are alive and disease free.
  • EFS was reduced with an increasing number of prognostic factors (Karnofsky performance status, KPS <90, chemotherapy-resistant disease and >or=3 chemotherapy regimens prior to transplant <or=1 vs >or=2; P=0.049).
  • Disease progression was the most common cause of death (n=10, 23%).
  • Intensive VCB is an effective and well-tolerated preparative regimen for relapsed and refractory HL auto-HSCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Graft Survival. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation, Autologous. Treatment Failure

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071290.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


29. Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K: Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Oct;46(10):1477-87
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
  • Progressive disease is the major cause of treatment failure after autologous hematopoietic stem cell transplantation for relapsed or refractory non-Hodgkin's lymphoma.
  • An augmented high-dose regimen of cyclophosphamide 7,200 mg/m2, carmustine 300 - 400 mg/m2, and etoposide 2,400 mg/m2 (CBV) was developed in an attempt to improve disease control post-transplant.
  • Sixty-seven adult patients received augmented CBV followed by infusion of unpurged autologous peripheral blood stem cells.
  • Thirty seven patients had relapsed after standard chemotherapy, 28 patients had primary refractory disease, and 2 patients had transformed lymphoma in first partial response.
  • Risk factors for disease progression were histologic involvement of marrow by lymphoma and infusion of increased numbers of CD34 + cells per kg in the stem cell autograft.
  • The outcome for patients with relatively chemorefractory disease (defined as 25 - 49% reduction in tumor volume after salvage chemotherapy) was no different than that for patients with chemosensitive disease.
  • Compared to standard high-dose CBV regimens, augmented CBV does not appear to have substantially improved disease control.
  • [MeSH-major] Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194894.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00750-310649; United States / NCRR NIH HHS / RR / M01 RR00750-310698; United States / NCRR NIH HHS / RR / M01 RR750
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


30. Leahy MF, Seymour JF, Hicks RJ, Turner JH: Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 20;24(27):4418-25
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
  • RESULTS: Ninety-one patients were entered onto the trial: 78 patients (86%) had follicular lymphoma, six patients (7%) had mucosa-associated lymphoid tissue/marginal zone lymphoma, and seven patients (8%) had small lymphocytic lymphoma.
  • CONCLUSION: 131I-rituximab radioimmunotherapy of relapsed or refractory indolent NHL achieves high ORR and CR rates with minimal toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Iodine Radioisotopes / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Rituximab. Survival Analysis. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Treatment Outcome. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


31. Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Pacquement H, Soussain C, Carde P, Salhi R, Zanni M, Decaudin D: A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients. Anticancer Drugs; 2008 Mar;19(3):309-15
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
  • The aim of this study was to assess the efficacy of a gemcitabine-containing regimen in pretreated Hodgkin's lymphoma (HL) patients.
  • Relapsed or refractory HL patients treated with gemcitabine, used alone or in combination with other cytotoxic agents, were retrospectively reviewed.
  • On univariate analysis, two adverse factors at progression were significant for response to gemcitabine-based regimen: stage III-IV disease and hemoglobin level was less than 10.5 g/dl.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Hemoglobins / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510178.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


32. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW: Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Sep;12(9):965-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
  • High-dose chemotherapy followed by blood or marrow transplantation (BMT) is generally considered the best salvage option for patients with relapsed diffuse large-B-cell non-Hodgkin's lymphoma (DLCL).
  • We reviewed the clinical outcome of 183 patients with relapsed DLCL who underwent BMT at Johns Hopkins University in 1985-2001.
  • The allo-BMT recipients had a higher proportion of patients with chemoresistant disease (P = .004) and had received more chemotherapy before BMT (P = .02).
  • The auto-BMT recipients were older (P < .001) and were of more advanced-stage disease (P = .01).
  • The 3-year OS for patients with sensitive disease was 51.9% after allo-BMT and 46.2% after auto-BMT (log-rank, P = .38).
  • For patients with resistant disease, the 3-year OS was 12.1% after allo-BMT and 19.1% after auto-BMT (log rank, P = .08).
  • In multivariate analysis, significant predictors of death were disease sensitivity (hazard rate [HR], 0.3; 95% confidence interval [CI] 0.2-04; P < .001), age >40 years (HR, 2.42; 95% CI, 1.7-3.4; P < .001), and stage at diagnosis (HR, 1.2; 95% CI, 1.0-1.4; P = .04).
  • The 3-year event-free survival (EFS) for patients with sensitive disease was 52.7% after allo-BMT and 42.0% after auto-BMT (log-rank, P = .29).
  • For patients with resistant disease, the 3-year EFS was 6.2% after allo-BMT and 19.4% after auto-BMT (log-rank, P = .1).
  • The 3-year relapse rate in patients with resistant disease was 75.0% after allo-BMT and 69.9% after auto-BMT (log-rank, P = .58).
  • In multivariate analysis, only disease sensitivity status (HR, 0.4; 95% CI, 0.2-2.1; P < .001) and age >40 years (HR, 1.7; 95% CI, 1.1-2.9; P = .03) appear to have a significant impact on relapse.
  • Mortality from lymphoma was 26.6% in allo-BMT recipients and 43.5% in auto-BMT recipients (P = .02).
  • Auto-BMT and allo-BMT produced similar survival for patients with relapsed DLCL.
  • For patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was achieved at the cost of greater TRM.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920563.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Mabed M, Al-Kgodary T: Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas. Bone Marrow Transplant; 2006 Apr;37(8):739-43
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
  • A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg/kg/day for 2 days), etoposide (15 mg/kg/day for 2 days) and carboplatine (400 mg/m(2)/day for 2 days), together with autologous non-cryopreserved peripheral blood stem cells was used for treatment of relapsed (29 patients) and refractory (three patients) patients with non-Hodgkin's lymphoma (NHL).
  • Fifteen of the 32 patients (49%) were alive and disease free at a median follow-up of 18 months (range 10-96 months) for all surviving patients.
  • The estimated 2-year overall survival (OS) and disease free survival (DFS) for all patients were 50 and 43%, respectively.
  • Twelve patients died of relapse or progressive disease, two patients died of infection and one patient died of cardiac cause.
  • High-dose chemotherapy with short-duration chemotherapy and non-cryopreserved bone marrow (BM) is an effective and safe treatment modality for patients with relapsed or resistant NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neutrophils / metabolism. Odds Ratio. Stem Cells / metabolism. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501587.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


34. Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY: [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):465-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: So far, there is still no standard salvage regimen for relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • This study was to evaluate the efficacy and safety of DICE regimen, as a salvage regimen, in treating patients with relapsed or refractory intermediate and high grade NHL.
  • METHODS: Thirty-five patients with relapsed or refractory intermediate and high grade NHL, who had been pretreated with chemotherapy dominated by CHOP or CHOP-like regimen with a median of 6 cycles (ranged 2-12 cycles), were salvaged by DICE regimen from Jun.
  • Elevated serum lactate dehydrogenase (LDH) and bulky disease were high risk factors of the efficacy of DICE regimen (P < 0.05).
  • The response to DICE reginmen was an independent prognostic factor of patients with relapsed or refractory NHL (P = 0.001).
  • CONCLUSIONS: DICE regimen is a safe and effective salvage regimen for the patients with relapsed or refractory intermediate and high grade advanced NHL.
  • Elevated serum LDH and bulky disease are the adverse prognostic factors.
  • The response to DICE regimen may directly influence survival time of patients with relapsed or refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Transplantation, Autologous

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820071.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


35. Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF: Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant; 2009 Jul;44(2):89-96
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
  • High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL).
  • We retrospectively reviewed clinical data of patients with relapsed NHL treated at our institution with i.v.
  • We identified 43 patients (24 men, 19 women, median age 50) with diffuse large B-cell lymphoma (n=28), follicular lymphoma (n=8), mantle cell lymphoma (n=4) and peripheral T-cell lymphoma (n=3).
  • The 100-day mortality was 9%: sepsis (n=1), pneumonia (n=1) and hepatic veno-occlusive disease (n=2).
  • BU/CY is a safe and effective conditioning regimen for autologous SCT in relapsed NHL.
  • [MeSH-major] Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169287.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


36. Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, Diehl V, Josting A: Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma; 2005 Jul;46(7):1017-22
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
  • High-dose chemotherapy followed by autologous stem cell transplantation can improve the outcome of relapsed and refractory Hodgkin's disease (HD) patients.
  • The objective of the trial was to determine the mobilizing potential of the DHAP salvage regimen (dexamethasone, cytarabine, cisplatin) for the collection of peripheral blood stem cells (PBSC) in patients with relapsed HD.
  • These results demonstrate that the salvage chemotherapy regimen, such as DHAP combined with G-CSF, can be successfully used to mobilize PBSC in HD patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cells / metabolism. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / drug effects. Cisplatin / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019552.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


37. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol; 2005 Jan 20;23(3):461-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
  • PURPOSE: To determine the maximum outpatient dose of iodine-131 tositumomab (up to 0.75 Gy) combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem-cell transplantation (ASCT) for the treatment of chemotherapy-resistant relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Twenty-three patients with chemotherapy-refractory or multiply-relapsed B-cell NHL were treated in a phase I trial combining iodine-131 tositumomab (ranging from 0.30 to 0.75 Gy total-body dose [TBD]) with high-dose BEAM followed by ASCT.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antigens, CD20. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Iodine Radioisotopes. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Radioimmunotherapy. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534357.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / iodine-131 anti-B1 antibody; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


38. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE: Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant; 2005 May;35(10):943-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
  • A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20).
  • Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26).
  • In all, 16 patients expired (TRM n=8, disease progression n=8).
  • RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease / etiology. Humans. Leukocyte Transfusion. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806128.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL: A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant; 2005 Mar;35(6):557-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
  • There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT).
  • We developed a prognostic model for event-free survival (EFS) post-BMT based on HD patient characteristics measured at the time of autologous (auto) or allogeneic (allo) BMT.
  • Between 1/1991 and 12/2001, 64 relapsed or refractory HD patients received an auto (n=46) or allo (n=18) BMT.
  • Significant multivariate predictors of shorter EFS were chemotherapy-resistant disease, KPS <90 and > or =3 chemotherapy regimens pre-BMT.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation. Prognosis
  • [MeSH-minor] Adult. Cause of Death. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft Survival. Humans. Male. Middle Aged. Models, Theoretical. Multivariate Analysis. Salvage Therapy. Survival Analysis. Time. Transplantation, Autologous. Transplantation, Homologous


40. Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C: ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med; 2006 Sep;21(3):159-64
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
  • BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials.
  • METHODS: Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study.
  • CONCLUSIONS: ESHAP regimen is effective in Korean patients suffering with relapsed or refractory NHLs, but a more effective salvage modality is needed because of the short duration of remission and the insignificant impact on long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone. Survival Analysis. Treatment Failure

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):12-20 [10561013.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):33-7 [10073149.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 2):12-6 [15042529.001]
  • [Cites] Blood. 1978 Jul;52(1):85-95 [350316.001]
  • [Cites] Cancer Res. 1981 Jan;41(1):25-30 [7192598.001]
  • [Cites] Blood. 1982 Sep;60(3):693-7 [7104493.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Semin Hematol. 1987 Apr;24(2 Suppl 1):21-5 [2438778.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1388-92 [2776103.001]
  • [Cites] Ann Oncol. 1991 Jan;2 Suppl 1:31-2 [1904269.001]
  • [Cites] Ann Oncol. 1991 Jun;2(6):431-5 [1722697.001]
  • [Cites] Ann Oncol. 1993 Jan;4(1):63-7 [8435365.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1573-82 [7687667.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Ann Oncol. 1994 May;5(5):453-6 [8075052.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1734-41 [7602363.001]
  • [Cites] Hematol Oncol Clin North Am. 1997 Oct;11(5):937-47 [9336723.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):621-4 [12378012.001]
  • (PMID = 17017664.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; ESHAP regimen
  • [Other-IDs] NLM/ PMC3890718
  •  go-up   go-down


41. Morris E, Mackinnon S: Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci; 2005 Feb;32(1):73-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
  • Twenty-one patients received DLI for MRD, persistent disease or relapse and 15 received DLI for mixed hematopoietic chimerism.
  • Patients with relapsed LG-NHL and CLL achieve excellent PFS with extremely low TRM and GVHD, even when matched family donors are unavailable.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737876.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


42. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer; 2010 Dec 7;103(12):1783-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • BACKGROUND: we conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).
  • METHODS: forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg(-1) mapatumumab every 21 days.
  • In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses.
  • Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Receptors, TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Br J Cancer. 2010 Feb 2;102(3):506-12 [20068564.001]
  • [Cites] J Pathol. 2003 Jul;200(3):327-35 [12845629.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):618-24 [9401075.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):501-10 [16098063.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1346-52 [16638930.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1390-5 [17416859.001]
  • [Cites] J Urol. 2007 May;177(5):1894-9 [17437844.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4556-64 [17671142.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5528s-5534s [17875785.001]
  • [Cites] Adv Exp Med Biol. 2008;615:127-58 [18437894.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3450-5 [18519776.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):82-90 [18255187.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5584-90 [19690193.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3058-65 [11698291.001]
  • (PMID = 21081929.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / mapatumumab
  • [Other-IDs] NLM/ PMC3008610
  •  go-up   go-down


43. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2005 Feb 1;23(4):667-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies.
  • RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.
  • In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%).
  • Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study.
  • CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bortezomib. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):657-8 [15613690.001]
  • (PMID = 15613697.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


44. Ballova V, Ladicka M, Vranovsky A, Lakota J: Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Neoplasma; 2008;55(5):428-36
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
  • With the aim to evaluate the long term outcome after high-dose chemotherapy and autologous stem cell transplantation (HDCT+ASCT) in patients with relapsed or refractory Hodgkin's lymphoma (HL) we performed a retrospective analysis of patients transplanted at our centre.
  • Between January 1993 and December 2005, 126 consecutive patients with relapsed or refractory HL in the age of 16 to 65 years underwent HDCT+ASCT at our centre and were enrolled in this retrospective analysis.
  • In univariate analysis, chemosensitive disease and increased LDH were the strongest prognostic factors for PFS and OS.
  • Our results confirm the efficacy of HDCT+ASCT in relapsed or refractory HL with acceptable toxicity.
  • [MeSH-major] Antigens, CD34 / therapeutic use. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation / methods. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Analysis. Transplantation Conditioning. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665754.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


45. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP, Cancer Leukemia Group B: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol; 2007 Jun;18(6):1071-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
  • BACKGROUND: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkin's lymphoma (HL).
  • CONCLUSIONS: GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426059.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA12449; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 30IQX730WE / Polyethylene Glycols; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


46. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P: Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica; 2007 Apr;92(4):568-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
  • We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Boronic Acids / administration & dosage. Boronic Acids / adverse effects. Bortezomib. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Female. Humans. Male. Middle Aged. Pyrazines / administration & dosage. Pyrazines / adverse effects. Recurrence. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488673.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00148018
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Letter; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


47. Chaar BT, Salem P, Petruska PJ: Procarbazine for non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):637-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine for non-Hodgkin's lymphoma.
  • Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma.
  • It is most commonly used in the treatment of Hodgkin's disease.
  • The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's lymphoma fell out of favor with the advent of CHOP.
  • We report two patients with relapsed and/or refractory follicular lymphoma that achieved a complete and durable remission with a prolonged course of daily procarbazine.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Procarbazine / therapeutic use
  • [MeSH-minor] Adult. Alkylating Agents / therapeutic use. Antineoplastic Agents / pharmacology. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Monoamine Oxidase Inhibitors / pharmacology. Remission Induction. Stem Cell Transplantation / methods

  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690522.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Monoamine Oxidase Inhibitors; 35S93Y190K / Procarbazine
  •  go-up   go-down


48. Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N: Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer; 2006 Jun 19;94(12):1770-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.
  • We present the long-term results of 18 chemotherapy relapsed indolent (N = 12) or transformed (N = 6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar) therapy study.
  • Two patients were not treated due to disease progression during dosimetry.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Antineoplastic Agents / toxicity. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Survival Rate. Time. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1986 Oct;4(10):1470-80 [3531422.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4336-42 [12036859.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):627-32 [1708835.001]
  • [Cites] Lancet. 1992 Jul 4;340(8810):1-4 [1351599.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6476-81 [1423295.001]
  • [Cites] N Engl J Med. 1993 Aug 12;329(7):459-65 [7687326.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Ann Endocrinol (Paris). 1996;57(3):166-76 [8949411.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):447-53 [9012472.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8 Suppl):14S-20S [9708566.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):712-9 [15613695.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Apr;20(2):185-8 [15869453.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4576-82 [15731177.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5696-704 [16110029.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]
  • [Cites] Cancer Immunol Immunother. 2006 Dec;55(12):1451-8 [16496145.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):897-906 [12610191.001]
  • [Cites] J Nucl Med. 2003 Mar;44(3):465-74 [12621016.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1263-70 [12663713.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1606-12 [12738671.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1469-79 [15084620.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4429-31 [15016644.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2654-61 [15159414.001]
  • [Cites] Clin Lymphoma. 2004 Sep;5(2):98-101 [15453924.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1784-90 [15471849.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • (PMID = 16685263.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / iodine-131 anti-B1 antibody
  • [Other-IDs] NLM/ PMC2361356
  •  go-up   go-down


49. Fan Y, Huang ZY, Luo LH, Yu HF: [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]. Ai Zheng; 2008 Nov;27(11):1222-5
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) after front-line therapy remains poor.
  • Gemcitabine is effective in treating lymphoma and, when combined with cisplatin, is effective for some solid tumors.
  • This study was to evaluate the efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive NHL, and observe the adverse events.
  • METHODS: Patients with relapsed or refractory aggressive NHL, measurable disease, and had received previously at least one chemotherapy regimen were enrolled and treated with GDP regimen (gemcitabine 1000 mg/m2 on Days 1 and 8, dexamethasone 20-40 mg on Days 1-3, and cisplatin 25 mg/m2 on Days 1-3) every 3 weeks.
  • Five (20.8%) patients had complete response, 9 had partial response, 8 had stable disease, and 2 had progressive disease.
  • CONCLUSION: GDP regimen is an effective and relatively nontoxic salvage chemotherapy regimen for relapsed or refractory aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / adverse effects. Cisplatin / therapeutic use. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Salvage Therapy. Stem Cell Transplantation. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000458.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; GDP protocol
  •  go-up   go-down


50. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE: Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica; 2008 Feb;93(2):257-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
  • BACKGROUND: The role of reduced-intensity conditioning allogeneic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma remains poorly defined.
  • DESIGN AND METHODS: Fifty-eight patients with relapsed/refractory Hodgkin's lymphoma underwent RIC and allogeneic stem cell transplantation from a matched related donor (MRD; n=25) or a matched unrelated donor (MUD; n=33).
  • Disease status at transplant was refractory relapse (n=28) or sensitive relapse (n=30).
  • The cumulative incidence of acute (grade II-IV) graft-versus-host disease in the first 100 days was 28% (MRD vs. MUD 12% vs. 39%, p=0.04).
  • The cumulative incidence of chronic graft-versus-host disease at any time was 73% (MRD vs. MUD 57% vs. 85%, p=0.006).
  • Projected 2-year overall and progression-free survival rates are 64% (49-76%) and 32% (20-45%), with 2-year disease progression/relapse at 55% (43-70%).
  • There was no statistically significant differences in overall survival progression-free survival, and disease progression/relapse between MRD and MUD transplants.
  • There was a trend for the response status pretransplant to have a favorable impact on progression-free survival (p=0.07) and disease progression/relapse (p=0.049), but not on overall survival (p=0.4) CONCLUSIONS: Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in progression-free survival Hodgkin's lymphoma is associated with a significant reduction in transplant-related mortality, with comparable results in MRD and MUD allografts.
  • [MeSH-major] Hodgkin Disease / therapy. Melphalan / administration & dosage. Myeloablative Agonists / administration & dosage. Stem Cell Transplantation. Tissue Donors. Transplantation Conditioning. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Hospitals, University. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies. Recurrence. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223284.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS641633; NLM/ PMC4238917
  •  go-up   go-down


51. Siddiqui N, Al-Diab AI: Nodular lymphocyte predominant Hodgkin's lymphoma. Saudi Med J; 2005 Feb;26(2):241-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin's lymphoma.
  • OBJECTIVE: To describe the clinicopathological features, treatment, treatment outcome and sequelae of patients with nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) in a Saudi population.
  • METHODS: This is a retrospective review of 29 patients with lymphocyte predominant Hodgkin's lymphoma treated at 2 major hospitals (King Khalid University Hospital and Security Forces Hospital) in Riyadh, Kingdom of Saudi Arabia from 1985 to 2000.
  • RESULTS: On pathological reappraisal of the 29 cases, 3 patients had nodular sclerosis Hodgkin's lymphoma and 4 patients were reclassified as lymphocyte rich classical Hodgkin's lymphoma.
  • Twenty-two patients were identified to have nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL).
  • Nineteen (86%) patients had an early stage (Ann Arbor stage I and II) disease, 2 had stage III and one patient had a stage IV.
  • Four patients relapsed following the primary therapy.
  • CONCLUSION: Our results are consistent with the previous series reported from Western countries and confirm that patients with NLPHL have a characteristic clinical and pathological profile that distinguish it from other types of Hodgkin's lymphoma.
  • The disease tends to run an unusual course and although most patients achieve an excellent response to therapy there is a tendency to relapse.
  • Treatment remains controversial; however, recent understanding of the molecular pathogenesis of NLPHL could lead to modification of current therapeutic approach to this disease.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunophenotyping. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770298.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


52. Rao R, Shammo JM, Enschede SH, Porter C, Adler SS, Venugopal P, Gregory SA: The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma; 2005 Jun;6(1):26-30
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
  • PURPOSE: The goal of this study was to evaluate the efficacy of the fludarabine/cyclophosphamide combination in patients with relapsed chronic lymphocytic lymphoma (CLL) and low-grade non-Hodgkin's lymphoma (NHL) and to assess the impact of adding granulocyte-macrophage colony-stimulating factor (GM-CSF) to this regimen in a randomized fashion.
  • Fourteen patients (52%) exhibited a partial response, and 6 patients (22%) had stable disease.
  • CONCLUSIONS: The combination of fludarabine and cyclophosphamide is a well-tolerated and effective treatment regimen for patients with relapsed CLL and low-grade NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Neoplasm Staging. Neutropenia / chemically induced. Patient Selection. Recurrence. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989703.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


53. Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A: Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol; 2005 Mar 1;23(7):1522-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
  • PURPOSE: To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone.
  • PATIENTS AND METHODS: From 4,754 patients registered in the database of the German Hodgkin Study Group from 1988 to 1999, 624 patients were identified with progressive disease (n = 202), or with early (n = 170) or late (n = 252) relapsed HD.
  • Patient characteristics were: median age, 36 years; progressive disease, 47%; early relapse, 23%; late relapse, 30%; and "B" symptoms, 14%.
  • Eighty-five percent of the patients relapsed after cyclophosphamide, vincristine, procarbazine, and prednisone/doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP/ABVD) -like regimens; 8% after bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimens, 7% after first-line radiotherapy alone.
  • CONCLUSION: SRT offers an effective treatment for selected subsets of patients with relapsed or refractory HD.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Failure. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632410.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol
  •  go-up   go-down


54. Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D, Kaminer L, Williams S, Duffey S, Variakojis D, Singhal S, Tallman MS, Mehta J, Winter JN, Gordon LI: Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol; 2007 Apr;18(4):679-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
  • BACKGROUND: The standard approach to treatment of relapsed/refractory Hodgkin's lymphoma (HL) is high-dose chemotherapy conditioning followed by autologous hematopoietic stem-cell transplantation (aHSCT).
  • We report the results of a prospective phase I/II clinical trial of accelerated hyperfractionated total lymphoid irradiation (TLI) immediately followed by high-dose chemotherapy for relapsed/refractory HL.
  • CONCLUSIONS: Sequential TLI/chemotherapy conditioning for relapsed/refractory HL is safe and associated with excellent long-term survival rates.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307757.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 109613-A1; United States / NCI NIH HHS / CA / T32 CA 079447
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


55. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol; 2005 Apr 1;23(10):2240-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
  • PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL).
  • HD-R of 1,000 mg/m(2) was administered again days 1 and 8 after transplantation.
  • Disease-free survival was 67% (95% CI, 51% to 79%) for the study group and 43% (95% CI, 26% to 60%) for the control group (P = .004).
  • CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Carmustine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Melphalan / administration & dosage. Middle Aged. Rituximab. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800314.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


56. Greco M, Valsecchi M, Niccodemi C, Presas J, Corrado C, Winkel M: [Limphomatous meningitis as recurrence site in Hodgkin's disease]. Medicina (B Aires); 2006;66(4):332-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limphomatous meningitis as recurrence site in Hodgkin's disease].
  • [Transliterated title] Meningitis linfomatosa como sitio de recaída en la enfermedad de Hodgkin.
  • Intracraneal manifestations of Hodgkin's Disease (HD) are extremely rare, with an estimated incidence rate of approximately 0.5%.
  • We describe a case of a 40 year-old male with mixed cellularity type HD who developed neurological manifestations as relapsed disease.
  • The patient died from progressive disease refractory to third line chemotherapy.
  • We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / chemically induced. Leukoencephalopathy, Progressive Multifocal / pathology. Magnetic Resonance Imaging. Male. Paraneoplastic Syndromes / pathology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977969.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; ESHAP regimen
  •  go-up   go-down


57. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, Todisco E, Bramanti S, Mazza R, Russo F, Timofeeva I, Santoro A: Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol; 2007 Feb;82(2):122-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
  • We designed a prospective study to evaluate the feasibility and efficacy of tandem high-dose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL).
  • Tandem HDCT is feasible and effective in patients with relapsed or refractory HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prospective Studies. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019686.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; Q6C979R91Y / vinorelbine; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; BEAM protocol
  •  go-up   go-down


58. Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A: Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest; 2005;23(1):13-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
  • This study was performed to determine the clinical activity and safety of weekly low-dose paclitaxel (90 mg/m2) given as a 1-hour infusion in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL).
  • Cycles were repeated as long as there was no disease progression or unacceptable toxicity.
  • Paclitaxel given in this dose and schedule has modest activity in previously treated non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Paclitaxel / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Resistance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Invest. 2005;23(1):100-2 [15779874.001]
  • [CommentIn] Cancer Invest. 2005;23(6):572 [16203667.001]
  • (PMID = 15779863.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 14520
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest; 2006 Oct;24(6):593-600
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • We designed a multicenter Phase II trial to prospectively evaluate the efficacy and safety of the combination of rituximab with the DHAP regimen (dexamethasone, high-dose cytarabine, cisplatin) in patients who relapsed after or were resistant to a CHOP-like regimen.
  • A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prospective Studies. Rituximab. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982464.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


60. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jan 20;26(3):455-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
  • PURPOSE: To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT).
  • The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / immunology. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Aug 20;26(24):4045-6; author reply 4046-7 [18711200.001]
  • (PMID = 18086796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


61. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y: Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci; 2008 Jan;99(1):179-84
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • The management of relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) remains challenging.
  • We investigated the efficacy and safety of salvage chemoimmunotherapy (CHASER) in patients with relapsed or refractory B-NHL who had radiographically measurable disease and adequate major organ function.
  • The treatment was repeated every 3 weeks up to a total of four courses in the absence of disease progression.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematopoietic Stem Cell Mobilization. Humans. Immunotherapy / methods. Middle Aged. Rituximab. Stem Cell Transplantation

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991293.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


62. Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C: Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs; 2010 Aug;28(4):516-22
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • We evaluated the efficacy and safety of yttrium-90-ibritumomab tiuxetan ((90)Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by ASCT in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
  • Histologies were diffuse large B-cell (n = 14), follicular (n = 2), mantle cell (n = 2), and Burkitt lymphoma (n = 1).
  • CONCLUSION: In conclusion, (90)Y-ibritumomab with Bu/Cy/E and ASCT is feasible in patients with relapsed or refractory B-cell NHL, without increased toxicity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Resistance, Neoplasm / drug effects. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / prevention & control. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Busulfan / adverse effects. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Secondary Prevention. Transplantation Conditioning / methods. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547918.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


63. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol; 2006 May;17 Suppl 4:iv18-24
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND: The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
  • We evaluated the clinical activity, toxicity and mobilizing capacity of a new salvage regimen, which combines gemcitabine and oxaliplatin with ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20(+) NHL.
  • RESULTS: Fourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study.
  • CONCLUSIONS: Based on the results of this pilot study, we conclude that the R-GIFOX regimen is feasible, tolerable, effective and able to mobilize peripheral stem cells in patients with relapsed and refractory aggressive NHL.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702180.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


64. Mukherji D, Pettengell R: Pixantrone maleate for non-Hodgkin's lymphoma. Drugs Today (Barc); 2009 Nov;45(11):797-805
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pixantrone maleate for non-Hodgkin's lymphoma.
  • The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice.
  • There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission.
  • Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study.
  • On the basis of these data, the United States Food and Drug Administration is considering pixantrone for use in adult patients with relapsed or refractory aggressive and indolent non-Hodgkin's lymphoma on a fast-track basis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Isoquinolines / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Animals. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Topoisomerase II Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 20126672.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoquinolines; 0 / Topoisomerase II Inhibitors; F5SXN2KNMR / pixantrone
  • [Number-of-references] 31
  •  go-up   go-down


65. Bommer M, Pauls S, Greiner J: Challenging complications of treatment--human herpes virus 6 encephalitis and pneumonitis in a patient undergoing autologous stem cell transplantation for relapsed Hodgkin's disease: a case report. Virol J; 2009;6:111
MedlinePlus Health Information. consumer health - Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging complications of treatment--human herpes virus 6 encephalitis and pneumonitis in a patient undergoing autologous stem cell transplantation for relapsed Hodgkin's disease: a case report.
  • CASE REPORT: This case demonstrates a severe symptomatic HHV-6 infection with encephalitis and pneumonitis after autologous stem cell transplantation of a patient with relapsed Hodgkin's disease.
  • [MeSH-major] Encephalitis, Viral / virology. Herpesvirus 6, Human / isolation & purification. Hodgkin Disease / complications. Pneumonia / virology. Roseolovirus Infections / diagnosis. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):887-91 [16611785.001]
  • [Cites] Int J Hematol. 2006 Dec;84(5):432-7 [17189225.001]
  • [Cites] J Infect Dis. 2006 Jan 1;193(1):68-79 [16323134.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):820-5 [15700258.001]
  • [Cites] Diagn Microbiol Infect Dis. 2005 Aug;52(4):275-80 [15936168.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):932-40 [15824982.001]
  • [Cites] Br J Haematol. 2004 Sep;126(5):690-6 [15327521.001]
  • [Cites] Leukemia. 2002 May;16(5):958-9 [11986964.001]
  • [Cites] Bone Marrow Transplant. 2001 Sep;28(5):473-7 [11593320.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):563-6 [17637686.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(11):705-9 [17401392.001]
  • (PMID = 19619326.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2718875
  •  go-up   go-down


66. Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW: A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Ann Hematol; 2006 May;85(5):301-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
  • In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), we combined theophylline, pentostatin, and chlorambucil at two dose levels (cohort I: 30 mg/m(2); cohort II: 20 mg/m(2)) on a 21-day cycle for up to six courses.
  • We employed a phase I/II design to determine feasibility, define the maximum tolerated dose (MTD), and explore the impact of biologic modulation on response and time to progression (TTP) in 20 patients with relapsed or refractory CLL and NHL.
  • Significant activity was observed in patients with B-cell CLL and follicular lymphoma (FL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chlorambucil / administration & dosage. Chlorambucil / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Pentostatin / administration & dosage. Pentostatin / adverse effects. Recurrence. Remission Induction. Survival Rate. Theophylline / administration & dosage. Theophylline / adverse effects

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518606.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 395575MZO7 / Pentostatin; C137DTR5RG / Theophylline
  •  go-up   go-down


67. Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ: LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant; 2007 Jan;39(1):41-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
  • High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed Hodgkin's lymphoma.
  • We have analysed 67 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) conditioning for relapsed (n=61) or primary refractory (n=6) Hodgkin's lymphoma.
  • In multivariate analysis mixed cellularity classical or lymphocyte-depleted classical histology subtype and haemoglobin level of 10 g/dl or less at the time of ASCT were identified as risk factors for worse OS, whereas stage III or IV disease at diagnosis and disease status at ASCT other than complete or partial remission predicted inferior PFS.
  • LACE followed by ASCT is an effective treatment for the majority of patients with chemosensitive relapsed Hodgkin's lymphoma and a proportion of chemorefractory patients also benefit.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115062.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


68. Massa FS, Rolón JM, Pavlovsky S: Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplantation. Hematology; 2007 Dec;12(6):487-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis with myeloid metaplasia in a patient with relapsed Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplantation.
  • We present a case of a 24-year-old male with relapsed Hodgkin lymphoma (HL) with no involvement of his bone marrow who underwent AHSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / therapy. Primary Myelofibrosis / etiology
  • [MeSH-minor] Adult. Humans. Male. Neoplasms, Second Primary. Recurrence. Transplantation, Autologous


69. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


70. Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A: Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Ann Hematol; 2005 Aug;84(8):517-25
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
  • Patients with primary progressive or refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) have a particularly poor prognosis.
  • Patients aged 18-55 years with primary progressive or refractory relapsed HD and aggressive NHL were included.
  • Patients with bulky disease (>5 cm) or residual lymphoma received involved field radiotherapy.
  • Twenty-five patients were included (HD=10, NHL=15, median age 34 years).
  • Two patients with HD achieved a CR and five patients a PR [response rate (RR) 70%].
  • Of the eight patients (56%) with treatment failure, three had progressive disease and five died from peritransplant complications.
  • [MeSH-major] Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Male. Middle Aged. Probability. Remission Induction. Survival Analysis. Transplantation, Autologous. Treatment Failure

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759115.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Pereira J, Bellesso M, Pracchia LF, Neto AE, Beitler B, de Almeida Macedo MC, Dias LC, Dorlhiac-Llacer PE, Dulley FL, Chamone D: Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. Leuk Res; 2006 Jun;30(6):681-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
  • BACKGROUND: The purpose of this retrospective study was to investigate the efficacy, toxicity and mobilization rate after modified Magrath IVAC (mIVAC) chemotherapy regimen prescribed in relapsed disease (RD) or primary refractory disease (PRD) in aggressive non-Hodgkin lymphoma (NHL).
  • The most frequent histopathological subgroup was diffuse large B-cell lymphoma (DLCL-B) (n=21/24), 13 (54%) were considered RD and 11 (46%) PRD.
  • Eighty-eight percent (14 out of 16) of patients with chemosensitive disease to mIVAC underwent autologous stem cell transplantation (ASCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / prevention & control. Lymphoma, Non-Hodgkin / prevention & control. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Brazil. Cytarabine / administration & dosage. Developing Countries. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Recurrence. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288806.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IVAC protocol
  •  go-up   go-down


72. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol; 2005 Aug;16(8):1359-65
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
  • BACKGROUND: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor prognosis.
  • PATIENTS AND METHODS: Inclusion criteria were age 18-65 years, histologically proven primary progressive or relapsed aggressive NHL and eligibility for HDCT.
  • RESULTS: Fifty-seven patients (median age 43 years, range 24-65) were enrolled: 23 (40%) patients were refractory to primary therapy and 34 (60%) patients had relapsed NHL.
  • CONCLUSIONS: We conclude that this regimen is feasible, tolerable and effective in patients with relapsed NHL.
  • In contrast, the results in patients with progressive disease are unsatisfactory.
  • This program is currently being modified by addition of rituximab for patients with relapsed aggressive NHL.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939712.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


73. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T: Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol; 2008 Jan;86(2):211-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
  • Treatment for patients with refractory or relapsed primary CNS lymphoma (PCNSL) remains unsatisfactory.
  • Topotecan is an intravenous topoisomerase I inhibitor with good CSF penetration and documented efficacy in patients with relapsed systemic non-Hodgkin's lymphoma.
  • In this study 15 patients with refractory or relapsed PCNSL were treated with intravenous topotecan (1.5 mg/m(2)) for five consecutive days during each 21-day cycle.
  • Three patients had stable disease at the end of topotecan treatment.
  • Six patients (40%) had progressive disease during treatment.
  • Our study shows that topotecan, as a salvage therapy in patients with relapsed or refractory PCNSL, is associated with an overall response proportion of 40% and should be considered in patients who have failed prior methotrexate-based chemotherapy and/or whole brain irradiation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome


74. Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA, Toze CL: Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant; 2008 Nov;42(9):601-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.
  • Outcome is poor with conventional therapy for relapsed transformed non-Hodgkin's lymphoma (NHL).
  • We therefore studied 40 consecutive patients who received allogeneic SCT for relapsed composite and transformed NHL (25 transformed, 8 composite (same site) and 7 discordant (different sites)) with related (n=25) and unrelated donors (n=15) to evaluate long-term outcome.
  • Death occurred in similar proportions due to relapsed NHL (n=14) or treatment-related complications (transplant-related mortality, TRM; n=15).
  • The cumulative incidence of TRM was 36% at 3 years and disease relapse was 42% at 5 years.
  • [MeSH-major] Living Donors. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Survival Rate. Transplantation Conditioning / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695664.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO: Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma; 2007 Apr;48(4):683-90
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
  • Between January 2001 and September 2005, 19 patients with progressive B-cell non-Hodgkin's lymphoma were treated with a cohort-specific dose of yttrium-90 ibritumomab tiuxetan (0.10 - 0.20 mCi/kg) to determine appropriate dosing in patients who had previously received high-dose chemotherapy and autologous stem cell transplantation (ASCT).
  • A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Stem Cell Transplantation / methods. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454625.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


76. Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA: A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther; 2009 Aug;86(2):190-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
  • [MeSH-major] Aminopterin / analogs & derivatives. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Body Size. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mucositis / prevention & control
  • [MeSH-minor] Adult. Aged. Area Under Curve. Biomarkers / blood. Drug Administration Schedule. Female. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / pharmacology. Humans. Incidence. Male. Methylmalonic Acid. Middle Aged. Models, Statistical. Predictive Value of Tests. Recurrence. Severity of Illness Index. Vitamin B 12 / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474785.001).
  • [ISSN] 1532-6535
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1UL1RR024156; United States / FDA HHS / FD / R01 FD0003498-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Folic Acid Antagonists; 8LL8S712J7 / Methylmalonic Acid; JYB41CTM2Q / Aminopterin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


77. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C, Zhang H, Huebsch L: Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol; 2006 Oct;85(10):723-9
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
  • Autologous stem cell transplantation (ASCT) has emerged as a viable option for the treatment of relapsed follicular non-Hodgkin's lymphoma.
  • Outpatient ASCT with total body irradiation is feasible, safe, and effective for patients with relapsed follicular lymphoma.
  • [MeSH-major] Ambulatory Care. Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carmustine / administration & dosage. Carmustine / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Gastrointestinal Diseases / etiology. Gastrointestinal Diseases / mortality. Humans. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neutropenia / etiology. Neutropenia / mortality. Podophyllotoxin / administration & dosage. Podophyllotoxin / adverse effects. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832675.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol; CBV protocol
  •  go-up   go-down


78. Klimm B, Schnell R, Diehl V, Engert A: Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica; 2005 Dec;90(12):1680-92
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment and immunotherapy of Hodgkin's lymphoma.
  • The treatment of Hodgkin's lymphoma has changed significantly over the last decades, rendering this entity one of the most curable human cancers.
  • To date, about 80% of patients achieve long-term disease-free survival.
  • Approaches for relapsed Hodgkin's lymphoma comprise salvage radiotherapy, salvage chemotherapy and high-dose chemotherapy followed by autologous stem cell transplantation.
  • In recent years, the introduction of effective salvage high-dose therapy and a better understanding of prognostic factors have remarkably improved the management of relapsed Hodgkin's lymphoma.
  • Here, we review new aspects in the treatment of primary and relapsed Hodgkin's lymphoma as well as recent immunotherapeutic approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Immunotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Antigens, CD30 / immunology. Case Management. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Ferritins / immunology. Hematopoietic Stem Cell Transplantation. Humans. Immunoconjugates / therapeutic use. Lymphatic Irradiation. Male. Middle Aged. Radiotherapy, Adjuvant. Rituximab. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330443.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Immunoconjugates; 0 / iratumumab; 4F4X42SYQ6 / Rituximab; 9007-73-2 / Ferritins
  • [Number-of-references] 78
  •  go-up   go-down


79. Ng AK, Li S, Recklitis C, Diller LR, Neuberg D, Silver B, Mauch PM: Health practice in long-term survivors of Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2008 Jun 1;71(2):468-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health practice in long-term survivors of Hodgkin's lymphoma.
  • PURPOSE: To compare the health practice of Hodgkin's lymphoma (HL) survivors and their siblings, and to assess the impact of socioeconomic status and disease history on health practice of HL survivors.
  • Lower educational level (p = 0.0004) and history of relapsed HL (p = 0.03) were independent predictors for smoking, moderate/heavy alcohol use, and/or physical inactivity.
  • Survivors with history of relapsed HL were also more likely to engage in unhealthy habits.
  • [MeSH-major] Health Behavior. Hodgkin Disease. Siblings. Socioeconomic Factors. Survivors
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Cross-Sectional Studies. Health Services / utilization. Health Status. Health Surveys. Humans. Middle Aged. Physical Examination / statistics & numerical data. Self-Examination / statistics & numerical data. Sex Factors. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Healthy Aging.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234434.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • The total dose administered to the abdomen was 18-20 Gy at the rate of 1.5-1.8 Gy per daily fraction, followed by a boost to gross disease up to 20 Gy.
  • Thirteen patients, six with follicular and seven with aggressive tumors, had refractory relapsed tumors after achieving one or more complete remissions.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • Out-of-field recurrence occurred more frequently in initial stage III and IV disease.
  • It is less effective in patients with primary refractory NHL than in those with refractory relapsed NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Aleknavicius E, Valuckas KP, Aleknaviciene B, Norkiene L, Smailyte G: [Treatment results of Hodgkin's lymphoma]. Medicina (Kaunas); 2009;45(8):615-23
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of Hodgkin's lymphoma].
  • During last decades, there are strengthening attitudes to optimize the treatment of Hodgkin's lymphoma considering prognostic groups and risk factors.
  • In 83% of cases, classic nodular sclerotic Hodgkin's lymphoma was diagnosed.
  • Advanced-, intermediate-, and early-stage disease was diagnosed in 55%, 38%, and 7% of cases, respectively.
  • The patients with early-stage disease underwent four ABVD chemotherapy courses; 88% of them underwent radiotherapy afterwards.
  • The patients with intermediate-stage disease underwent 4-6 courses of ABVD or in minor cases (12% of patients with intermediate-stage disease) - 4 standard BEACOPP chemotherapy courses.
  • After this treatment, 88% of patients with intermediate-stage disease underwent radiotherapy.
  • Patients with advanced-stage disease underwent 8 escalate (44%) or standard BEACOPP (29%) chemotherapy courses.
  • One hundred seven patients (94%) after primary treatment achieved complete remission, in 7 patients (6%) primary progression was observed, 12 patients (11%) relapsed, and 8 patients died.
  • Overall survival and event-free survival in patients with early-stage disease was 100%.
  • Overall survival in patients with early/intermediate- and advanced-stage disease was 95.1% and 84.0%, respectively.
  • Event-free survival in patients with early/intermediate- and advanced-stage disease was 91.7% and 76.2%, respectively.
  • In the groups of intermediate- and advanced-stage disease, the results of treatment were worse in the subgroup, which underwent extended-field radiotherapy (P<0.05).
  • Overall survival in the group of patients with advanced-stage disease was the best who underwent ABVD scheme, but the event-free survival (70.6%) and disease-free survival (81.3%) in ABVD subgroup were worse compared to BEACOPP subgroup.
  • According to our results, there was no statistically significant difference in survival of patients with advanced-stage disease who underwent or did not radiotherapy (P>0.05).
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Data Interpretation, Statistical. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773620.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


82. Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B: Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE. J Chemother; 2008 Oct;20(5):640-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
  • We report the outcomes of 45 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) treated with a combination of ifosfamide, carboplatinum and etoposide (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods.
  • Changing from IMVP to ICE does not substantially improve the outcome of patients with relapsed or refractory aggressive NHL.
  • Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048695.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


83. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia; 2007 Nov;21(11):2316-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
  • The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved.
  • A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors.
  • Histologies were non-Hodgkin's lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL), n=14) and Hodgkin's disease (HD, n=32).
  • The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001).
  • Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04).
  • On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of HD (HR=3.5), and acute GVHD (HR=5.9).
  • [MeSH-major] Lymphoma / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Stem Cells / cytology. Stem Cells / metabolism. Time Factors. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597807.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


84. Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M: Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma; 2006 Mar;47(3):473-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
  • Patients with aggressive NHL who fail initial treatment or subsequently relapse have a very poor outcome and less than 20-25% achieve a prolonged disease-free interval with salvage therapies.
  • Between November 1999 and September 2002, 69 patients with relapsed or refractory aggressive NHL were treated with ViGePP regimen, every 4 weeks up to six courses.
  • At the end of planned chemotherapy patients could receive additional radiotherapy on residual masses or on sites of previously bulky disease.
  • Thirty patients were refractory to therapy and 36 patients had relapsed after remission obtained with previous therapy.
  • At the end of therapy, complete remission (CR) rate was 23%, 3-year relapse free survival rate was 40% and 3-year overall survival rate was 25% for the whole series (29% and 20% for relapsed and refractory patients, respectively).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, Non-Hodgkin / therapy. Prednisone / administration & dosage. Procarbazine / administration & dosage. Salvage Therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):576-7 [16886269.001]
  • (PMID = 16396771.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


85. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.
  • Sixty-eight patients with HD (23 newly diagnosed and 45 with relapsed/refractory disease, one patient treated both de novo and years later in relapse) were treated with the MVC regimen (mitoxantrone 8 mg/m(2)/day i.v. days 1 - 3; vinblastine 8 m/m(2)/day days 1 and 22; and CCNU (lomustine) 100 mg/m(2) on day 1, repeated at 6 - 8 weeks) in a single-arm Phase II study.
  • Four secondary myeloid leukemias occurred, three in de novo, and one in the relapsed/refractory group, at a median follow-up of 14 years.
  • MVC regimen for HD is highly active, for both de novo and relapsed/refractory disease, with high response rates and survival that compare favourably with the results obtained by high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


86. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N: Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest; 2008 May;26(4):401-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
  • BACKGROUND: High dose chemotherapy with autologous stem cell transplantation is currently the treatment of choice for relapsed or refractory lymphoma patients.
  • In this study, our aim was to compare the efficacy and toxicity profiles of DHAP (cytosine arabinoside, cisplatin and dexamethasone) and ICE (ifosfamide, carboplatin and etoposide) regimens in the salvage treatment of relapsed and refractory lymphoma.
  • PATIENTS AND METHODS: In this retrospective analysis, 53 patients with primary refractory or relapsed Hodgkin's disease (HD) (n = 13) or non-Hodgkin lymphoma (NHL) (n = 40) who received ICE or DHAP salvage regimen were included.
  • Response could be evaluated in 49 patients (36 NHL and 13 HD).
  • CONCLUSION: Although the toxicity profiles of both ICE and DHAP regimens were similar in the treatment of patients with relapsed or refractory HD or NHL, ICE seems to have higher rates of response than DHAP regimen does.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Immunotherapy. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Retrospective Studies. Rituximab. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443961.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DHAP protocol; ICE protocol 3
  •  go-up   go-down


87. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • At a median follow-up of 32 months (range, 3 - 61), nine patients relapsed/progressed and eleven patients died.
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


88. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A: Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica; 2007 Feb;92(2):269-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.
  • In 50 patients with Hodgkin's lymphoma BLyS levels were higher in newly diagnosed patients (median 2.0 ng/mL, range <0.3-56.0) and relapsed patients (8.7 ng/mL, range 1.5-71.5) than in 93 healthy donors (<0.3 ng/mL, range <0.3-0.5).
  • Serum BLyS levels may have prognostic significance in Hodgkin's lymphoma.
  • [MeSH-major] B-Cell Activating Factor / blood. B-Cell Activating Factor / physiology. Hodgkin Disease / blood. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Case-Control Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296586.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / B-Cell Activating Factor
  •  go-up   go-down


89. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer; 2005 Apr 25;92(8):1352-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
  • There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma.
  • We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.
  • In patients with chemo-resistant disease, the RR was 63%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Drug Resistance, Neoplasm. Humans. Methylprednisolone / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):543-9 [8573532.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Bone Marrow Transplant. 1997 Jul;20(1):21-6 [9232251.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):525-9 [9261520.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3264-9 [9779700.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):351-4 [10355582.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):943-7 [10509156.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 May;11(5):595-7 [10907954.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Biochem Pharmacol. 2001 Jun 1;61(11):1401-8 [11331076.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):786-92 [11843810.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):17-21 [12504621.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):970-7 [12648066.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):621-30 [12537665.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1963-70 [12799644.001]
  • [Cites] Rev Mal Respir. 2003 Apr;20(2 Pt 1):201-6 [12844017.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] Oncology. 2004;66(3):197-200 [15218310.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):45-9 [15245607.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • (PMID = 15812553.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2361993
  •  go-up   go-down


90. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol; 2006 Jan;78(1):1-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
  • BACKGROUND: Short course chemotherapy followed by radiotherapy is a standard treatment for early Hodgkin's disease.
  • PATIENTS AND METHODS: From 1980 to 1996, 61 patients with stage I and II supradiaphragmatic Hodgkin's disease were treated with chemotherapy alone at the Royal Marsden Hospital.
  • RESULTS: After a median follow-up of 6.5 years, 24 patients had relapsed giving a 5-year relapse rate of 40%.
  • Twenty patients (83%) relapsed in the initially involved sites of disease and this was the sole site of recurrence in 11 (45%) of patients.
  • Review of detailed imaging data (available in 9 out of 11 patients with recurrences in initial sites of disease) showed that the relapses were always in the initially involved nodes.
  • CONCLUSION: After chemotherapy alone in early stage HD most initial recurrences are nodal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309770.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


91. Bogatyrëva TI, Kravchenko TV, Afanasova NV, Pavlov VV, Mardynskiĭ IuS: [Low-dose accelerated hyperfractionated radiotherapy for local control of chemoresistant Hodgkin's disease (a prospective randomized trial)]. Vopr Onkol; 2006;52(5):544-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-dose accelerated hyperfractionated radiotherapy for local control of chemoresistant Hodgkin's disease (a prospective randomized trial)].
  • The results are evaluated of the combined treatment of 154 patients with relapsed refractory Hodgkin's disease, which was conducted using standard dosage of conventional chemotherapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose Fractionation. Female. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168363.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


92. Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM: Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. Ann Oncol; 2006 Nov;17(11):1693-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease.
  • BACKGROUND: To determine the long-term treatment outcome and late effects of mantle irradiation alone in selected patients with early-stage Hodgkin's disease.
  • METHODS: Between 1988 and 2000, 87 patients with pathologic stage (Ann Arbor) I-IIA or clinical stage IA Hodgkin's disease were entered on to a prospective trial of mantle irradiation alone.
  • Thirteen of 87 patients (15%) relapsed at a median of 30 months (range 5-62).
  • All 13 patients who relapsed are alive without evidence of disease at a median of 84 months (range 30-156) post-salvage therapy.
  • CONCLUSION: In selected patients with early-stage Hodgkin's disease, mantle irradiation alone has an excellent long-term survival rate, comparing favorably with the previous standard treatment of extended-field radiation therapy and the current standard of combined modality therapy.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018702.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A: Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol; 2007 Apr;78(4):322-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
  • BACKGROUND: We analysed the feasibility and efficacy of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) in patients with refractory or progressive Hodgkin's disease (HD) after high-dose chemotherapy (HDCT).
  • PATIENTS AND METHODS: Fourteen patients with HD received allo-SCT with RIC: eleven patients had a human leucocytes antigen-identical related donor and three a matched unrelated donor.
  • Six had chemoresistant disease and eight had chemosensitive one at the time of transplantation.
  • Grade II acute graft-vs.-host disease (GvHD) developed in six of the 14 patients (43%).
  • Estimated overall survival at 1 and 2 yr was 93% and 73%, respectively, for the whole population, 83% and 44% respectively for patients with chemoresistant disease and 100% for those with chemosensitive disease.
  • Estimated progression-free survival at 1 yr was 36%; 62.5% for chemosensitive patients and 0% for those with chemoresistant disease.
  • CONCLUSIONS: In conclusion, allo-SCT with fludarabine-based RIC is a feasible procedure, without TRM in HD patients relapsed and refractory after HDCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Graft vs Host Disease / therapy. Humans. Male. Middle Aged. Recurrence. Survival Rate. Transplantation, Autologous / adverse effects. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253967.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D: Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol; 2010 Oct;89(10):1045-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
  • The effectiveness of reduced-intensity conditioning allogeneic stem cell transplantation (allo- RIC) compared with high-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) in Hodgkin's disease (HD) and in non-Hodgkin's lymphoma (NHL) patients remains poorly defined.
  • The purpose of the study was to demonstrate the usefulness of auto-SCT or allo-SCT, employing a RIC regimen in refractory or relapsed NHL or HD patients.
  • We analyzed the outcome of 71 patients with advanced disease.
  • Twenty-three NHL and 14 HD patients received an allo-RIC using fludarabine, cyclophosphamide, and low-dose busulfan as the conditioning regimen.
  • Sixteen NHL and 18 HD patients received auto-SCT using cyclophosphamide and etoposide as conditioning regimen.
  • The relapse rate was higher in autografted patients, both in NHL and HD.
  • Both auto-SCT and allo-RIC appear to be valid treatments for poor-risk patients with relapsed or refractory lymphoma who could not otherwise be cured with conventional salvage regimens.
  • [MeSH-major] Ambulatory Care. Hematopoietic Stem Cell Transplantation / methods. Lymphoma / prevention & control. Lymphoma / surgery. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20490794.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


95. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M: Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol; 2006 Aug;17(8):1296-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.
  • BACKGROUND: It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients.
  • PATIENTS AND METHODS: Between June 2003-September 2004, in our institute, 40 newly-diagnosed patients with advanced stage HD were consecutively treated with ABVD chemotherapy for six cycles.
  • After treatment, among eight patients who were PET-2+, seven showed refractory disease and one had relapse after 3 months.
  • All four patients with MRU at the PET-2 became PET- during the further four cycles and, after treatment, three were in complete response (CR) and one relapsed after 5 months.
  • CONCLUSIONS: The PET use for early (after two cycles) response assessment in HD patients is a significant step forward and has the potential to help physicians make crucial decisions about further treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766583.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Harrington KJ, Michalaki VJ, Vini L, Nutting CM, Syrigos KN, A'hern R, Harmer CL: Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience. Br J Radiol; 2005 May;78(929):405-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience.
  • A retrospective review was conducted of patients treated for thyroid non-Hodgkin's lymphoma (TNHL) at the Royal Marsden Hospital between 1936 and 1996 to determine the effect of radiotherapy (RT) on outcome.
  • Significantly more patients treated with IFRT relapsed locally (52% vs 27%).
  • EFRT alone for Stage I, but not for Stage II disease, yielded acceptable rates of local control and disease free survival with doses of at least 40 Gy.
  • These historical data strongly support the addition of combination chemotherapy to the treatment regimen in all patients with Stage II disease.
  • Indeed, in recent years this has become the standard of care for all cases of thyroid lymphoma unless the histology is of marginal zone type (mucosa associated lymphoma tissue (MALT) lymphoma).
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Thyroid Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. London. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845932.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2005 Jul 20;23(21):4643-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
  • PURPOSE: (18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma.
  • We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease.
  • MATERIALS AND METHODS: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded.
  • RESULTS: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 +/- 3.1 v 19.6 +/- 9.3; P < .01) and relapsed (SUV, 6.3 +/- 2.7 v 18.1 +/- 10.9; P = .04) disease.
  • Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV <or= 13.
  • A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%.
  • CONCLUSION: FDG uptake is lower in indolent than in aggressive lymphoma.
  • Patients with NHL and SUV > 10 have a high likelihood for aggressive disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • (PMID = 15837966.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U: Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol; 2005 Nov;84(12):796-801
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
  • The optimum therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) not qualifying for platinum-based and/or high-dose chemotherapy is not known.
  • GVP shows substantial activity in poor prognosis relapsed or refractory aggressive lymphomas and is generally well tolerated, but haematological toxicity is dose limiting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Infection / etiology. Infection / mortality. Leukopenia / etiology. Leukopenia / mortality. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Recurrence. Remission Induction. Thrombocytopenia / etiology. Thrombocytopenia / mortality. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041531.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


99. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Cox regression multivariate analysis showed that the survival rate was correlated to the value of international prognostic index (IPI), and whether the patient had primary refractory or relapsed disease, but was not correlated to sex, age, pathologic subtype, B symptoms, and bulky disease.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


100. Boleti E, Mead GM: ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol; 2007 Feb;18(2):376-80
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
  • BACKGROUND: We investigated whether administration of full-dose ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy without growth factors, and irrespective of the granulocyte count, caused treatment delays or increased the number of infective episodes, in patients with Hodgkin's lymphoma (HL).
  • All patients are currently disease-free, although three (7.8%) required salvage high-dose therapy (one relapsed and two with refractory disease).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071938.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down






Advertisement